Divalproex sodium (Depakote) vs valproate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABAergic neurotransmission · full Epilepsy pipeline

Divalproex sodium (Depakote)

Marketed by AbbVie

Approved in Epilepsysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

valproate

Rights held by AbbVie and partners; US product discontinued

Approved in Epilepsysmall molecule
Partial signal

NCT00004817 · Phase 3 · completed

The registry protocol outline and the published report (Temkin 1999) describe a randomized, double-blind, parallel-group trial: 379 patients were assigned to a 1-week course of phenytoin or a 1-month or 6-month course of valproate. The primary outcomes were seizure rates, which are clinical endpoints. Valproate did not prevent early or late post-traumatic seizures better than phenytoin, and mortality trended higher with valproate (13.4% vs 7.2%, p=0.07).

Reported efficacy

Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). (missed)

Result source: NCT00004817

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDivalproex sodium (Depakote)valproate
Seizure frequency, % change—Not posted · NCT00102713—Not posted · NCT00236717
50% responder rate—Not posted · NCT00102713—Not posted · NCT00236717
Seizure freedom—Not posted · NCT00102713—Not posted · NCT00236717

Seizure frequency, % change

Divalproex sodium (Depakote)
—Not posted · NCT00102713
valproate
—Not posted · NCT00236717

50% responder rate

Divalproex sodium (Depakote)
—Not posted · NCT00102713
valproate
—Not posted · NCT00236717

Seizure freedom

Divalproex sodium (Depakote)
—Not posted · NCT00102713
valproate
—Not posted · NCT00236717
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Divalproex sodium (Depakote): 2 of 4 rows · valproate: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDivalproex sodium (Depakote)valproate
Dropout rate
0%a
NCT00318929 · Phase na · registry result, not featured evidence
0.7%
NCT00088452 · Phase 3 · Absence Seizures, Epilepsy · phase 3
Discontinued due to AEs
—a
NCT00318929 · Phase na · registry result, not featured evidence
—
NCT00088452 · Phase 3 · Absence Seizures, Epilepsy · phase 3
Serious AEs
0%a
NCT00318929 · Phase na · registry result, not featured evidence
1.4%
NCT00088452 · Phase 3 · Absence Seizures, Epilepsy · phase 3
Most frequent reported AEs—
fatigue 12.2%
hostility 12.2%
personality change 10.9%
NCT00088452 · Phase 3 · Absence Seizures, Epilepsy · phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

valproate

Treatment Failure Free 58.2% (n=146) vs 29.5% (n=146) Lamotrigine @ 20wk
event count · % of participants
NCT00088452 · Phase 3 · Absence Seizures, Epilepsy · phase 3 · converted to % from 85 Participants as posted
show 1 more result
43.8% (n=146) vs 21.2% (n=146) Lamotrigine @ 52wk*
NCT00088452 · Phase 3 · Absence Seizures, Epilepsy · phase 3 · converted to % from 64 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Divalproex sodium (Depakote)'s landscape · valproate's landscape